Taysha Gene Therapies (TSHA) Misses Q2 EPS by 1c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q2 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Future Money Acquisition gets Nasdaq notice over late 10-Q filing
• KLX Energy narrows Q3 2026 revenue guidance, completes rights offering